Safety and Efficacy of GMX1777 in the Treatment of Refractory Solid Tumors or Lymphomas

Summary

GMX1777 is a water-soluble, intravenously-administered prodrug of GMX1778. GMX1777 is rapidly converted to GMX1778 in vivo. GMX1778 has potent anti-tumor activity against a variety of cell lines and models from different tumor origins.

Timeline

Start

2007-03

Primary completion

2009-07

Completion

2010-08

Outcome

Outcome not reported

Stopped (Business): “Study terminated prematurely due to financial constraints.”

Drugs

Indications